<DOC>
	<DOCNO>NCT00239746</DOCNO>
	<brief_summary>The purpose study test effect ibuprofen level number different protein ( call biomarkers ) cerebrospinal fluid ( CSF ) , blood , urine see whether ibuprofen influence certain biomarkers associate progression Alzheimer 's Disease .</brief_summary>
	<brief_title>BONSAI : Biomarkers Nonsteroidal Anti-Inflammatories</brief_title>
	<detailed_description>The hypothesis test possible role ibuprofen prevent AD detect change biomarkers AD . Eligible participant complete enrollment visit include : physical exam , neurological exam , neuropsychological testing , minor blood draw . At second visit , approximately 2 week later , participant undergo baseline lumbar puncture , issue either ibuprofen placebo take daily 6-12 week . Both participant clinicians mask treatment assignment . After 6-12 week , participant undergo second , final , lumbar puncture . This complete participant involvement study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Age 59 year old time first visit Family history one firstdegree relatives Alzheimerlike dementia Fluency write spoken English Willingness limit use Vitamin E ( &lt; 600 IU per day ) , Nonaspirin NSAIDs , Aspirin ( &lt; 81mg per day ) , Histamine H2 receptor antagonist , Gingko biloba extract duration study Ability intention participate regular study visit Provision inform consent History peptic ulcer disease complicate perforation , hemorrhage obstruction History uncomplicated peptic ulcer symptom 28 day prior first visit Clinically significant hypertension , anemia , liver disease , kidney disease Hypersensitivity aspirin NSAIDS Concurrent use warfarin , ticlopidine , type anticoagulant Concurrent use systemic corticosteroid Use ≥ 4 dos per week either follow 14 day prior first visit : Nonaspirin NSAIDs , Aspirin ( &gt; 81mg per day ) , Histamine H2 receptor antagonist Current plasma creatinine ≥1.5mg/dL Enrollment trial likely interfere BONSAI procedure affect treatment outcomes Cognitive impairment dementia</criteria>
	<gender>All</gender>
	<minimum_age>59 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Nonsteroidal Anti-inflammatories</keyword>
	<keyword>NSAIDS</keyword>
</DOC>